1-(5-((6-nitroquinazolin-4-yl)thio)-1,3,4-thiadiazol-2-yl)-3-(m-tolyl)urea

1-(5-((6-nitroquinazolin-4-yl)thio)-1,3,4-thiadiazol-2-yl)-3-(m-tolyl)urea (also known as compound 8c) is a synthetic small molecule belonging to a series of novel quinazoline derivatives conjugated with 1,3,4-thiadiazole and diaryl urea moieties. Designed as a potential antineoplastic agent, it functions as an inhibitor of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), a key tyrosine kinase that mediates tumor angiogenesis. In preclinical in vitro studies, the compound demonstrated antiproliferative activity against several human cancer cell lines, including A549 (lung cancer), MDA-MB-231 (triple-negative breast cancer), and MCF7 (hormone-dependent breast cancer). Molecular docking and dynamics simulations suggest that the compound interacts with the ATP-binding site of VEGFR-2. It is currently an academic research compound with no reported clinical development or commercial branding.